WHO WE ARE

Cardiawave was created at the end of 2014 as a result of a partnership of over 6 years between the academic laboratories Physics for Medicine Paris (INSERM/CNRS/ESPCI/PSL) and Langevin Institute (CNRS/INSERM/ESPCI), world leaders in ultrasound imaging and therapy, and the Georges Pompidou European Hospital (HEGP), a leader in the field of valve disease and cardiac ultrasound imaging.

Based at the business incubator of Paris Biotech Santé in Cochin and member of the national research consortium RHU Stop-AS and of the competitiveness cluster MEDICEN Paris Région, Cardiawave employs 26 people and has secured over €22M in funding since its inception.

With a quality management system that is EN ISO 13485:2016 certified since 2019, Cardiawave has developed Valvosoft®, a non-invasive ultrasound therapy medical investigational device for the treatment of calcific aortic stenosis (CAS), the most prevalent heart valve disease in adults and one of the most common causes of cardiovascular mortality worldwide. Cardiawave’s mission is to improve the quality of patient care by offering medical devices for non-invasive therapies.

Early 2019, Cardiawave was granted approval to perform a first-in-human feasibility clinical study (FIH‑I) in France and in the Netherlands enrolling 10 patients. Another study (FIH-II) has been approved in Serbia and started at the end of 2019. In 2020, Cardiawave obtained approval for an extension of its FIH-I increasing the study population up to 30 patients. This study extension is on-going.

A Research Letter presenting the preliminary results of the FIH-I has been published in Circulation on January 25, 2021.

SCIENTIFIC PUBLICATIONS

Awards & Honours